NEPHROPLUS logo

Nephrocare Health Services Limited Stock Price

NSEI:NEPHROPLUS Community·₹75.0b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 2 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

NEPHROPLUS Share Price Performance

₹747.25
276.00 (58.57%)
​
₹847.50
Fair Value
₹747.25
276.00 (58.57%)
11.8% undervalued intrinsic discount
₹847.50
Fair Value
Price ₹747.25
AnalystConsensusTarget ₹847.50
AnalystHighTarget ₹1,000.00
AnalystLowTarget ₹725.00

NEPHROPLUS Community Narratives

Fair Value
·
Fair Value ₹847.5 11.8% undervalued intrinsic discount

Dialysis Demand And International Expansion Will Support A Positive Long Term View

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Fair Value
·
Fair Value ₹1k 25.3% undervalued intrinsic discount

Rising Dialysis Demand And International Expansion Will Support A Stronger Long Term Outlook

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Fair Value
·
Fair Value ₹725 3.1% overvalued intrinsic discount

Clinic Expansion And International Policy Risks Will Pressure Long Term Dialysis Economics

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
NEPHROPLUS logo
Nephrocare Health Services
11.8% undervalued intrinsic discount
Updated

Dialysis Demand And International Expansion Will Support A Positive Long Term View

View narrative
Updated 8 Sep
Read Narrative
NEPHROPLUS logo
Nephrocare Health Services
3.1% overvalued intrinsic discount

Clinic Expansion And International Policy Risks Will Pressure Long Term Dialysis Economics

View narrative
Updated 13 Aug
Read Narrative
NEPHROPLUS logo
Nephrocare Health Services
25.3% undervalued intrinsic discount

Rising Dialysis Demand And International Expansion Will Support A Stronger Long Term Outlook

View narrative
Published 29 May
Read Narrative

Trending Discussion

No trending discussion available.

Updated Narratives

NEPHROPLUS logo

NEPHROPLUS: Overseas Subsidiary Support Will Drive Future Upside Potential

Fair Value: ₹847.5 11.8% undervalued intrinsic discount
1 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
NEPHROPLUS logo

NEPHROPLUS: Future Returns Will Balance Collateral Support And Margin Expectations

Fair Value: ₹725 3.1% overvalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
NEPHROPLUS logo

Rising Dialysis Demand And International Expansion Will Support A Stronger Long Term Outlook

Fair Value: ₹1k 25.3% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Flawless balance sheet with reasonable growth potential.

0 Risks
2 Rewards
View Full Analysis

Nephrocare Health Services Limited Key Details

₹10.5b

Revenue

₹6.4b

Cost of Revenue

₹4.1b

Gross Profit

₹3.2b

Other Expenses

₹851.1m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
8.48
38.82%
8.08%
2.1%
View Full Analysis

About NEPHROPLUS

Founded
2009
Employees
2294
CEO
Rohit Singh
WebsiteView website
www.nephroplus.com

Nephrocare Health Services Limited provides dialysis healthcare services through a chain of kidney care clinics and dialysis centers in India, Uzbekistan, Nepal, and the Philippines. It provides In-clinic dialysis, dialysis on call, home hemodialysis, holiday dialysis, and dialysis on wheels services. The company was incorporated in 2009 and is based in Hyderabad, India.

Recent NEPHROPLUS News & Updates

Narrative Update • Sep 08

NEPHROPLUS: Overseas Subsidiary Support Will Drive Future Upside Potential

Analysts have nudged their price target for Nephrocare Health Services higher from ₹771.25 to ₹847.50, citing updated assumptions around revenue growth, profit margins, a slightly lower discount rate, and a revised future P/E multiple. What's in the News for Nephrocare Health Services An upcoming board meeting is scheduled on Jun 22, 2026 to review the NephroPlus Employee Stock Option Scheme 2026 as recommended by the Nomination and Remuneration Committee, source, Key Developments.
Analysis Article • Aug 15

Nephrocare Health Services Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

The quarterly results for Nephrocare Health Services Limited ( NSE:NEPHROPLUS ) were released last week, making it a...
Narrative Update • Aug 13

NEPHROPLUS: Future Returns Will Balance Collateral Support And Margin Expectations

Analysts have raised the fair value estimate for Nephrocare Health Services from ₹660.00 to ₹725.00, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E levels as the key drivers of this change. What’s in the News for Nephrocare Health Services Board meeting scheduled on Jun 22, 2026 to consider the NephroPlus Employee Stock Option Scheme 2026, as recommended by the Nomination and Remuneration Committee, and to review provision of collateral or security support of up to ₹70 crore for NephroPlus Kidney Services Company in Saudi Arabia.

Recent updates

No updates

Nephrocare Health Services Limited Competitors

APOLLOHOSP logo

Apollo Hospitals Enterprise

Symbol: NSEI:APOLLOHOSP
Market cap: ₹1.3t
543220 logo

Max Healthcare Institute

Symbol: BSE:543220
Market cap: ₹1.0t
MANIPALHOS logo

Manipal Health Enterprises

Symbol: NSEI:MANIPALHOS
Market cap: ₹964.5b
FORTIS logo

Fortis Healthcare

Symbol: NSEI:FORTIS
Market cap: ₹681.3b
View more competitors